Global T Cell Specific Surface Glycoprotein CD28 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global T Cell Specific Surface Glycoprotein CD28 Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
T Cell Specific Surface Glycoprotein CD28 report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global T Cell Specific Surface Glycoprotein CD28 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Plaque Psoriasis and Solid Tumor are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for T Cell Specific Surface Glycoprotein CD28 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, T Cell Specific Surface Glycoprotein CD28 key manufacturers include Atox Bio Ltd, Bristol-Myers Squibb Co, Five Prime Therapeutics Inc, Johnson & Johnson and TheraMAB LLC, etc. Atox Bio Ltd, Bristol-Myers Squibb Co, Five Prime Therapeutics Inc are top 3 players and held % sales share in total in 2022.
T Cell Specific Surface Glycoprotein CD28 can be divided into FPT-155, FR-104, Lulizumab Pegol and Others, etc. FPT-155 is the mainstream product in the market, accounting for % sales share globally in 2022.
T Cell Specific Surface Glycoprotein CD28 is widely used in various fields, such as Plaque Psoriasis, Solid Tumor, Acute Renal Failure(ARF) and Others, etc. Plaque Psoriasis provides greatest supports to the T Cell Specific Surface Glycoprotein CD28 industry development. In 2022, global % sales of T Cell Specific Surface Glycoprotein CD28 went into Plaque Psoriasis filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global T Cell Specific Surface Glycoprotein CD28 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Atox Bio Ltd
Bristol-Myers Squibb Co
Five Prime Therapeutics Inc
Johnson & Johnson
TheraMAB LLC
Segment by Type
FPT-155
FR-104
Lulizumab Pegol
Others
Plaque Psoriasis
Solid Tumor
Acute Renal Failure(ARF)
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the T Cell Specific Surface Glycoprotein CD28 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of T Cell Specific Surface Glycoprotein CD28, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the T Cell Specific Surface Glycoprotein CD28 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of T Cell Specific Surface Glycoprotein CD28 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, T Cell Specific Surface Glycoprotein CD28 introduction, etc. T Cell Specific Surface Glycoprotein CD28 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of T Cell Specific Surface Glycoprotein CD28 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for T Cell Specific Surface Glycoprotein CD28 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, T Cell Specific Surface Glycoprotein CD28 key manufacturers include Atox Bio Ltd, Bristol-Myers Squibb Co, Five Prime Therapeutics Inc, Johnson & Johnson and TheraMAB LLC, etc. Atox Bio Ltd, Bristol-Myers Squibb Co, Five Prime Therapeutics Inc are top 3 players and held % sales share in total in 2022.
T Cell Specific Surface Glycoprotein CD28 can be divided into FPT-155, FR-104, Lulizumab Pegol and Others, etc. FPT-155 is the mainstream product in the market, accounting for % sales share globally in 2022.
T Cell Specific Surface Glycoprotein CD28 is widely used in various fields, such as Plaque Psoriasis, Solid Tumor, Acute Renal Failure(ARF) and Others, etc. Plaque Psoriasis provides greatest supports to the T Cell Specific Surface Glycoprotein CD28 industry development. In 2022, global % sales of T Cell Specific Surface Glycoprotein CD28 went into Plaque Psoriasis filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global T Cell Specific Surface Glycoprotein CD28 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Atox Bio Ltd
Bristol-Myers Squibb Co
Five Prime Therapeutics Inc
Johnson & Johnson
TheraMAB LLC
Segment by Type
FPT-155
FR-104
Lulizumab Pegol
Others
Segment by Application
Plaque Psoriasis
Solid Tumor
Acute Renal Failure(ARF)
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the T Cell Specific Surface Glycoprotein CD28 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of T Cell Specific Surface Glycoprotein CD28, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the T Cell Specific Surface Glycoprotein CD28 industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of T Cell Specific Surface Glycoprotein CD28 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, T Cell Specific Surface Glycoprotein CD28 introduction, etc. T Cell Specific Surface Glycoprotein CD28 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of T Cell Specific Surface Glycoprotein CD28 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.